ReviewJournal for immunotherapy of cancer2019
CAR-T cell therapy: a potential new strategy against prostate cancer.
Review in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of '-mabs'?The Journal of pathology · 2026Review
- Review
- Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next.NPJ vaccines · 2026Review
- Advancing CAR-T therapy in prostate cancer: overcoming the tumor microenvironment and enhancing efficacy.Frontiers in oncology · 2026Review
- Bispecific antibodies in metastatic castration-resistant prostate cancer: therapeutic strategies and frontier advances.World journal of urology · 2025Review
- Synergistic targeting strategies for prostate cancer.Nature reviews. Urology · 2025Review
- Targeting Aggressive Prostate Carcinoma Cells with Mesothelin-CAR-T Cells.Biomedicines · 2025Article
- Bolstering CD8Biology · 2025Review
- Evidence-Based Recommendations on the Use of Immunotherapies and Monoclonal Antibodies in the Treatment of Male Reproductive Cancers.Current oncology (Toronto, Ont.) · 2025Review
- Targeted and immunotherapeutic strategies for castration-resistant prostate cancer: emerging strategies, challenges, and future directions.Frontiers in immunology · 2025Review
- Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Revolutionizing Cancer Treatment: Unveiling the Power of CAR T-cell Therapy.Current pharmaceutical design · 2025Review
- T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.Cancer biology & therapy · 2024Review
- CAR-T-cell therapy in meningioma: current investigations, advancements and insight into future directions.Annals of medicine and surgery (2012) · 2024Review
- A novel nomogram model for lung adenocarcinoma subtypes based on RNA-modification regulatory genes.Heliyon · 2024Article
- CAR-T cell-derived exosomes: a new perspective for cancer therapy.Stem cell research & therapy · 2024Review
- Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors.Cancer cell international · 2024Review
- Long non-coding RNAs in drug resistance across the top five cancers: Update on their roles and mechanisms.Heliyon · 2024Review
- Cuproptosis Regulates Microenvironment and Affects Prognosis in Prostate Cancer.Biological trace element research · 2024Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is one of the main causes of cancer-related death in men. In the present immunotherapy era, several immunotherapeutic agents have been evaluated in PCa with poor results, possibly due to its low mutational burden. The recent development of chimeric antigen receptor (CAR)-T cell therapy redirected against cancer-specific antigens would seem to provide the means for bypassing immune tolerance mechanisms. CAR-T cell therapy has proven effective in eradicating hematologic malignancies and the challenge now is to obtain the same degree of in solid tumors, including PCa. In this study we review the principles that have guided the engineering of CAR-T cells and the specific prostatic antigens identified as possible targets for immunological and non-immunological therapies. We also provide a state-of-the-art overview of CAR-T cell therapy in PCa, defining the key obstacles to its development and underlining the mechanisms used to overcome these barriers. At present, although there are still many unanswered questions regarding CAR-T cell therapy, there is no doubt that it has the potential to become an important treatment option for urological malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.